Suggested Use: Two capsules twice daily or as directed by physician.
Mycoceutics® capsules, provided by Douglas Laboratories®, contain an array of beta-glucans and other active constituents derived from ten of the most healthful species of mushrooms. Mycoceutics is also fortified with an additional 30 mg of beta-1,3-glucan derived from purified yeast. Mushrooms used in Mycoceutics are grown under carefully monitored conditions to ensure that they never come in contact with heavy metals, pollutants, and contaminants. These mushrooms are specially cultivated to maximize polysaccharide content. As the mushrooms in Mycoceutics are cultivated and not wild-grown, no sensitive ecological areas are damaged to collect the mushrooms.
Mushrooms have been an integral component of folk medicine world wide for many centuries. Scientists are actively investigating the many healthful components of mushrooms, yet, several active constituents have already been identified. Polysaccharides, dietary fiber, lectins, and terpenoids have all been identified as beneficial components of certain mushroom species. Polysaccharides demonstrate potent immunomodulating activity in in vitro, animal, and clinical studies. Betaglucans are important polysaccharides found in mushrooms that enhance the body’s natural immune activity. Beta-1,3-glucans, as well as beta-1,4-glucans and beta-1,6-glucans activate macrophage function and release of nitric oxide and tumor necrosis factoralpha. Macrophages are one of the two primary phagocytic cells of the immune system. They are able to engulf and destroy foreign antigens. Macrophages also help govern the immune system, helping to initiate and direct specific immune responses. In stimulating macrophage activity, beta-glucans support the immune system by activating natural immune responses, rather than directly affecting foreign cells or entities.
No adverse effects have been reported.
Store in a cool, dry place, away from direct light. Keep out of reach of children.
Abel G, Czop JK. Stimulation of human monocyte beta-glucan receptors by glucan particles induces production of TNF-alpha and IL-1 beta. Int J Immunopharmacol 1992;14:1363-73. Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high risk surgical patients. Arch Surg 1994;129(11):1204-10. Battle J, Ha T, Li C, et al. Ligand binding to the (1–> 3) –beta-D-glucan receptor stimulates NFkappaB activation, but not apoptosis in U937 cells. Biochem Biophys Res Commun 1998;249(2):499-504. Chang R. Functional properties of edible mushrooms. Nutr Rev 1996;54 (11 pt 2):S91-3. de Filippe Jr J, da Rocha e Silva Jr M, Maciel FM, et al. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet 1993;177(4):383-8. Estrada A, Yun CH, Van Kessel A, et al. Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol 1997;41:991-8. Hashimoto T, Ohno N, Adachi Y, Yadomae T. Nitric oxide synthesis inmurine peritoneal macrophages by fungal beta-glucans. Biol Pharm Bull 1997;20:1006-9. Hoffman OA, Olson EJ, Limper AH. Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide. Immunol Lett 1993;37:19-25. Ohno N, Egawa Y, Hashimoto T, et al. Effect of beta-glucans on the nitric oxide synthesis by peritoneal macrophage in mice. Biol Pharm Bull 1996;19:608-12. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999;19(1):65-96. Wu D, Han SN, Bronson RT, et al. Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice. J Nutr 1997;128:193-197. Yoshioka S, ohno N, Miura T, et al. Immunotoxicity of soluble betaglucans induced by indomethacin treatment. FEMS Immunol Med Microbiol 1998;21:171-9.